In:
Gynecologic and Obstetric Investigation, S. Karger AG, Vol. 83, No. 1 ( 2018), p. 83-89
Abstract:
〈 b 〉 〈 i 〉 Aims: 〈 /i 〉 〈 /b 〉 The study aimed to do the following: (1) describe progression free survival (PFS) and overall survival (OS) of women with cervical cancer presenting with occult supraclavicular lymph node (SCLN) metastases, identified by positron emission tomography CT (PET-CT) and (2) compare OS of patients with isolated SCLN metastases to that of patients with SCLN and extranodal metastatic disease. 〈 b 〉 〈 i 〉 Methods: 〈 /i 〉 〈 /b 〉 Patients were identified retrospectively. Treatment intent was abstracted. PFS and OS in the high-dose chemo-radiotherapy (RT), palliative RT, and supportive treatment groups, as well as OS of patients with SCLN metastases only vs. SCLN and extranodal metastases were calculated. 〈 b 〉 〈 i 〉 Results: 〈 /i 〉 〈 /b 〉 Fourteen patients received high-dose chemo-RT, 32 received palliative RT, and 6 received supportive care ( 〈 i 〉 n 〈 /i 〉 = 52). Median PFS was 3 months in high-dose chemo-RT group and 1 month in palliative RT ( 〈 i 〉 p 〈 /i 〉 = ns). Median OS was 12 months in high-dose chemo-RT group, 7 months in palliative RT group, and 2 months in palliative care group ( 〈 i 〉 p 〈 /i 〉 = 0.05). OS was significantly different between patients with isolated SCLN disease vs. SCLN and extranodal disease, that is, 10.5 vs. 3 months ( 〈 i 〉 p 〈 /i 〉 = 0.009, 〈 i 〉 & #x03C7; 〈 /i 〉 〈 sup 〉 2 〈 /sup 〉 = 6.9). 〈 b 〉 〈 i 〉 Conclusions: 〈 /i 〉 〈 /b 〉 In this limited analysis, median OS of cervical cancer patients with PET/CT-positive SCLN metastases was the longest when treated with high-dose chemo-RT. Patients with SCLN and extranodal metastases experienced significantly shorter OS, as compared to patients with SCLN only disease.
Type of Medium:
Online Resource
ISSN:
0378-7346
,
1423-002X
Language:
English
Publisher:
S. Karger AG
Publication Date:
2018
detail.hit.zdb_id:
1482695-1
Permalink